Next 10 |
home / stock / tdsgf / tdsgf news
Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncol...
Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncolo...
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treat...
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo" ) is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnos...
Toronto, Ontario--(Newsfile Corp. - December 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), ( the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (A...
SMART Observational Study a Critical Step Toward Full Platform Availability Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), ( the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power ...
An Important Accreditation Milestone Achieved Towards Full Commercial Availability Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A), ( the "Company" or "Telo"), a biotech company pioneering the most comprehensive A.I. based ...
ASH is the world leader in supporting clinical and scientific hematology research Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") announces today that the American Society of Hematology (ASH) has accepted the...
Authorizes Telo to Offer its Laboratory Developed Tests ("LDT") from its Central Lab Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the " Company " or " Telo ") is pleased to announce that it has passed all requirements a...
2023-10-17 09:15:48 ET Palm Beach, FL – October 17, 2023 – FinancialNewsMedia.com News Commentary – Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US mult...
News, Short Squeeze, Breakout and More Instantly...
Teledata Singapore Ltd Company Name:
TDSGF Stock Symbol:
OTCMKTS Market:
Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncol...
Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncolo...
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treat...